Compounds > 2'-cyano-2'-deoxyarabinofuranosylcytosine
Page last updated: 2024-09-03

2'-cyano-2'-deoxyarabinofuranosylcytosine and paclitaxel

2'-cyano-2'-deoxyarabinofuranosylcytosine has been researched along with paclitaxel in 1 studies

Compound Research Comparison

Studies
(2'-cyano-2'-deoxyarabinofuranosylcytosine)		Trials
(2'-cyano-2'-deoxyarabinofuranosylcytosine)		Recent Studies (post-2010)
(2'-cyano-2'-deoxyarabinofuranosylcytosine)		Studies
(paclitaxel)		Trials
(paclitaxel)		Recent Studies (post-2010) (paclitaxel)
310631,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomy2'-cyano-2'-deoxyarabinofuranosylcytosine (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C1

Other Studies

1 other study(ies) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and paclitaxel

ArticleYear
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
    International journal of oncology, 2018, Volume: 52, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays

2018